Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
620
archived clinical trials in
ADHD

Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver Dysfunction
Pharmacokinetics of Orally Administered Dasotraline in Subjects With Mild, Moderate, and Severe Hepatic Dysfunction
Status: Enrolling
Updated:  12/1/2016
DaVita Clinical Research
mi
from
Minneapolis, MN
Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver Dysfunction
Pharmacokinetics of Orally Administered Dasotraline in Subjects With Mild, Moderate, and Severe Hepatic Dysfunction
Status: Enrolling
Updated: 12/1/2016
DaVita Clinical Research
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver Dysfunction
Pharmacokinetics of Orally Administered Dasotraline in Subjects With Mild, Moderate, and Severe Hepatic Dysfunction
Status: Enrolling
Updated:  12/1/2016
American Research Cororation (ARC), Texas Liver Instituete (TLI)
mi
from
San Antonio, TX
Study of the What the Body Does to the Drug in Subjects With Mild, Moderate, and Severe Liver Dysfunction
Pharmacokinetics of Orally Administered Dasotraline in Subjects With Mild, Moderate, and Severe Hepatic Dysfunction
Status: Enrolling
Updated: 12/1/2016
American Research Cororation (ARC), Texas Liver Instituete (TLI)
mi
from
San Antonio, TX
Click here to add this to my saved trials
Efficacy of Neuro+ Attention Training
Efficacy of NEURO+ Attention Training: A Randomized, Controlled, Blinded, Clinical Trial
Status: Enrolling
Updated:  12/20/2016
Neuropsychiatric Clinic at Carolina Partners in Mental HealthCare
mi
from
Raleigh, NC
Efficacy of Neuro+ Attention Training
Efficacy of NEURO+ Attention Training: A Randomized, Controlled, Blinded, Clinical Trial
Status: Enrolling
Updated: 12/20/2016
Neuropsychiatric Clinic at Carolina Partners in Mental HealthCare
mi
from
Raleigh, NC
Click here to add this to my saved trials
Association Between Smoking, Brain Activity, Genes, and ADHD
Smoking, Neurocircuitry and Genes in Adult ADHD
Status: Enrolling
Updated:  1/12/2017
2500 Red Hill Avenue
mi
from
Santa Ana, CA
Association Between Smoking, Brain Activity, Genes, and ADHD
Smoking, Neurocircuitry and Genes in Adult ADHD
Status: Enrolling
Updated: 1/12/2017
2500 Red Hill Avenue
mi
from
Santa Ana, CA
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
University of California at San Francisco
mi
from
San Francisco, CA
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Connecticut Clinical Research
mi
from
Cromwell, CT
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Connecticut Clinical Research
mi
from
Cromwell, CT
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Sarkis Clinical Trials
mi
from
Gainesville, FL
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Sarkis Clinical Trials
mi
from
Gainesville, FL
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Miami Research Associates
mi
from
South Miami, FL
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Miami Research Associates
mi
from
South Miami, FL
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Goldpoint Clinical Research
mi
from
Indianapolis, IN
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Goldpoint Clinical Research
mi
from
Indianapolis, IN
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Lake Charles Clinical Trials LLC
mi
from
Lake Charles, LA
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Lake Charles Clinical Trials LLC
mi
from
Lake Charles, LA
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Kennedy Krieger Institute
mi
from
Baltimore, MD
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Kennedy Krieger Institute
mi
from
Baltimore, MD
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Rochester Center for Behavioral Medicine
mi
from
Rochester Hills, MI
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Rochester Center for Behavioral Medicine
mi
from
Rochester Hills, MI
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
St Charles Psychiatric Associates - Midwest Research Group
mi
from
St. Charles, MO
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
St Charles Psychiatric Associates - Midwest Research Group
mi
from
St. Charles, MO
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Center For Emotional Fitness
mi
from
Cherry Hill, NJ
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Center For Emotional Fitness
mi
from
Cherry Hill, NJ
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Richard H. Weisler, MD, PA
mi
from
Raleigh, NC
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Richard H. Weisler, MD, PA
mi
from
Raleigh, NC
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Neuro-Behavioral Clinical Research, Inc.
mi
from
Canton, OH
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Neuro-Behavioral Clinical Research, Inc.
mi
from
Canton, OH
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Suburban Research Associates
mi
from
Media, PA
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Suburban Research Associates
mi
from
Media, PA
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Clinical NeuroScience Solutions, Inc.
mi
from
Memphis, TN
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Clinical NeuroScience Solutions, Inc.
mi
from
Memphis, TN
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
BioBehavioral Research of Austin at Specialty Clinic of Austin
mi
from
Austin, TX
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
BioBehavioral Research of Austin at Specialty Clinic of Austin
mi
from
Austin, TX
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Bayou City Research, Ltd.
mi
from
Houston, TX
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Bayou City Research, Ltd.
mi
from
Houston, TX
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
NeuroScience, Inc. (NSI)
mi
from
Herndon, VA
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
NeuroScience, Inc. (NSI)
mi
from
Herndon, VA
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
The Medical Research Network, LLC
mi
from
New York, NY
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
The Medical Research Network, LLC
mi
from
New York, NY
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Psychiatric And Behavioral Solutions
mi
from
Salt Lake City, UT
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Psychiatric And Behavioral Solutions
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Rambam Medical Center
mi
from
Haifa,
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Rambam Medical Center
mi
from
Haifa,
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Harmonex
mi
from
Dothan, AL
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Harmonex
mi
from
Dothan, AL
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Global Medical Institutes, LLC; Princeton Medical Institute
mi
from
Princeton, NJ
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Global Medical Institutes, LLC; Princeton Medical Institute
mi
from
Princeton, NJ
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
CNS Healthcare
mi
from
Orlando, FL
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
CNS Healthcare
mi
from
Orlando, FL
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Village Clinical Research Inc
mi
from
Oklahoma, OK
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Village Clinical Research Inc
mi
from
Oklahoma, OK
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Summit Research Network
mi
from
Portland, OR
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Summit Research Network
mi
from
Portland, OR
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
IPS Research Company
mi
from
Oklahoma City, OK
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
IPS Research Company
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Summit Research Network (Seattle) LLC
mi
from
Seattle, WA
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Summit Research Network (Seattle) LLC
mi
from
Seattle, WA
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Pharmacology Research Institute
mi
from
Los Alamitos, CA
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Pharmacology Research Institute
mi
from
Los Alamitos, CA
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Pharmacology Research Institute
mi
from
Newport Beach, CA
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Pharmacology Research Institute
mi
from
Newport Beach, CA
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
MCB Clinical Research Centers
mi
from
Colorado Springs, CO
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
MCB Clinical Research Centers
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Clinical Neuroscience Solutions, Inc.
mi
from
Jacksonville, FL
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Clinical Neuroscience Solutions, Inc.
mi
from
Jacksonville, FL
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Premier Psychiatric Research Institute, LLC
mi
from
Lincoln, NE
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Premier Psychiatric Research Institute, LLC
mi
from
Lincoln, NE
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Artemis Institute for Clinical Research
mi
from
San Diego, CA
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Artemis Institute for Clinical Research
mi
from
San Diego, CA
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Coastal Connecticut Research, LLC
mi
from
New London, CT
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Coastal Connecticut Research, LLC
mi
from
New London, CT
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Institute for Advanced Medical Research
mi
from
Alpharetta, GA
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Institute for Advanced Medical Research
mi
from
Alpharetta, GA
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Carolina Clinical Research, Inc.
mi
from
Charleston, SC
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Carolina Clinical Research, Inc.
mi
from
Charleston, SC
Click here to add this to my saved trials
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  1/18/2017
Dean Foundation - Middleton
mi
from
Middleton, WI
The MEASURE Study - A Phase 3 Study of MDX 1400 mg Daily Compared With Placebo in Adults With ADHD
A 10-week Randomized, Multicenter, Double-blind, Parallel, Fixed-dose Study of MDX (Metadoxine Immediate-release/Slow-release, Bilayer Tablet) 1400 mg Compared With Placebo in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 1/18/2017
Dean Foundation - Middleton
mi
from
Middleton, WI
Click here to add this to my saved trials
Efficacy and Safety of SPN-812 ER in Children With ADHD
Status: Enrolling
Updated:  5/4/2017
Florida Clinical Research Center LLC
mi
from
Maitland, FL
Efficacy and Safety of SPN-812 ER in Children With ADHD
Status: Enrolling
Updated: 5/4/2017
Florida Clinical Research Center LLC
mi
from
Maitland, FL
Click here to add this to my saved trials
A Phase I/IIa, Randomized, Double-Blind Study of the Safety and Efficacy of SPN-812 in Adults With ADHD
A Phase I/IIa Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of SPN-812 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/4/2017
Clinical Research Facility
mi
from
Bradenton, FL
A Phase I/IIa, Randomized, Double-Blind Study of the Safety and Efficacy of SPN-812 in Adults With ADHD
A Phase I/IIa Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of SPN-812 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/4/2017
Clinical Research Facility
mi
from
Bradenton, FL
Click here to add this to my saved trials
A Phase I/IIa, Randomized, Double-Blind Study of the Safety and Efficacy of SPN-812 in Adults With ADHD
A Phase I/IIa Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of SPN-812 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/4/2017
Clinical Research Facility
mi
from
Libertyville, IL
A Phase I/IIa, Randomized, Double-Blind Study of the Safety and Efficacy of SPN-812 in Adults With ADHD
A Phase I/IIa Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of SPN-812 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/4/2017
Clinical Research Facility
mi
from
Libertyville, IL
Click here to add this to my saved trials
A Phase I/IIa, Randomized, Double-Blind Study of the Safety and Efficacy of SPN-812 in Adults With ADHD
A Phase I/IIa Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of SPN-812 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/4/2017
Clinical Research Facility
mi
from
Owensboro, KY
A Phase I/IIa, Randomized, Double-Blind Study of the Safety and Efficacy of SPN-812 in Adults With ADHD
A Phase I/IIa Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of SPN-812 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/4/2017
Clinical Research Facility
mi
from
Owensboro, KY
Click here to add this to my saved trials
A Phase I/IIa, Randomized, Double-Blind Study of the Safety and Efficacy of SPN-812 in Adults With ADHD
A Phase I/IIa Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of SPN-812 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated:  5/4/2017
Clinical Research Facility
mi
from
Herndon, VA
A Phase I/IIa, Randomized, Double-Blind Study of the Safety and Efficacy of SPN-812 in Adults With ADHD
A Phase I/IIa Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of SPN-812 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
Status: Enrolling
Updated: 5/4/2017
Clinical Research Facility
mi
from
Herndon, VA
Click here to add this to my saved trials
Improving Medication Adherence in ADHD Adolescents
Improving Medication Adherence in ADHD Adolescents
Status: Enrolling
Updated:  8/8/2017
Florida International University Center for Children and Families
mi
from
Miami, FL
Improving Medication Adherence in ADHD Adolescents
Improving Medication Adherence in ADHD Adolescents
Status: Enrolling
Updated: 8/8/2017
Florida International University Center for Children and Families
mi
from
Miami, FL
Click here to add this to my saved trials
Using Telehealth to Deliver Mental Health Services in Primary Care Settings for Children in Underserved Areas
Using Telehealth to Deliver Mental Health Services in Primary Care Settings for Children in Underserved Areas
Status: Enrolling
Updated:  8/8/2017
Northeast Valley Health Corporation- Canoga Park
mi
from
Canoga Park, CA
Using Telehealth to Deliver Mental Health Services in Primary Care Settings for Children in Underserved Areas
Using Telehealth to Deliver Mental Health Services in Primary Care Settings for Children in Underserved Areas
Status: Enrolling
Updated: 8/8/2017
Northeast Valley Health Corporation- Canoga Park
mi
from
Canoga Park, CA
Click here to add this to my saved trials
Using Telehealth to Deliver Mental Health Services in Primary Care Settings for Children in Underserved Areas
Using Telehealth to Deliver Mental Health Services in Primary Care Settings for Children in Underserved Areas
Status: Enrolling
Updated:  8/8/2017
Northeast Valley Health Corporation- Pacoima
mi
from
Pacoima, CA
Using Telehealth to Deliver Mental Health Services in Primary Care Settings for Children in Underserved Areas
Using Telehealth to Deliver Mental Health Services in Primary Care Settings for Children in Underserved Areas
Status: Enrolling
Updated: 8/8/2017
Northeast Valley Health Corporation- Pacoima
mi
from
Pacoima, CA
Click here to add this to my saved trials
Using Telehealth to Deliver Mental Health Services in Primary Care Settings for Children in Underserved Areas
Using Telehealth to Deliver Mental Health Services in Primary Care Settings for Children in Underserved Areas
Status: Enrolling
Updated:  8/8/2017
Northeast Valley Health Corporation- San Fernando
mi
from
San Fernando, CA
Using Telehealth to Deliver Mental Health Services in Primary Care Settings for Children in Underserved Areas
Using Telehealth to Deliver Mental Health Services in Primary Care Settings for Children in Underserved Areas
Status: Enrolling
Updated: 8/8/2017
Northeast Valley Health Corporation- San Fernando
mi
from
San Fernando, CA
Click here to add this to my saved trials